Adeno-associated virus (AAV) vector manufacturing is a critical step in advancing gene therapies from research to clinical application. However, AAV process development and scale-up present significant technical and regulatory challenges. From upstream production to downstream purification and GMP readiness, developers require robust, scalable processes to ensure product quality and regulatory compliance.
AAV Vector Manufacturing: From Process Development to GMP Readiness
Challenges in AAV Vector Manufacturing and Scale-Up
AAV therapies hold remarkable potential for treating genetic disorders, but their development remains complex. Each serotype behaves differently; processes that work at small scale often falter when scaled up; and the regulatory expectations for viral vector production are evolving rapidly.
At eXmoor Pharma, we help gene therapy developers overcome these challenges with a clear, strategic approach to AAV process development. Whether you’re translating early research into a GMP-ready process or refining an established platform for clinical supply, our team combines 20 years of consultancy heritage with hands-on vector development expertise to move your therapy forward, faster.
We don’t just develop processes — we design them with the end in mind.
Our AAV team supports clients from preclinical concept through to GMP readiness, combining upstream, downstream, and analytical expertise within one facility. Our goal is to develop processes that are scalable, reproducible, and ready for seamless technology transfer into GMP manufacture.
Our capabilities include:
Choosing the Right AAV CDMO Partner
AAV developers face a crowded CDMO landscape, where many offer similar services but few combine consultancy-led insight with end-to-end delivery. Choosing the right partner can mean the difference between scalable success and costly rework.
Common pain points we help solve include:
- Uncertain scalability – processes that perform well at research scale but lose yield or quality during transfer.
- Product-specific complexity – novel serotypes, capsids, or payload designs can introduce challenges that standard platform approaches do not fully address.
- Analytical uncertainty – more complex AAV products may require deeper product characterisation and fit-for-purpose analytical strategies.
- Fragmented service models – disconnected PD and GMP teams that slow progress and risk data loss.
- Limited flexibility – rigid CDMO platforms that restrict development options or retain IP.
- Regulatory complexity – evolving standards that demand foresight and compliance planning.
At eXmoor Pharma, we address these challenges through a uniquely integrated model that brings consultancy, process development, analytics and GMP manufacturing together as part of one seamless workflow. This ensures clarity, speed, and technical continuity from early design to clinical delivery.
Expert Insights
Why early CMC input matters in AAV development
In this video, Clare Blue, Senior CMC Consultant, outlines how early CMC involvement helps developers think beyond initial proof of concept and define a strategy that considers manufacturability, product quality, scalability, packaging, and supply requirements from the outset.
For complex AAV therapies, these factors can vary significantly between products, so involving CMC expertise early can help identify risks sooner and reduce the likelihood of costly changes later in development.
An early warning sign in AAV scale-up
Daphné Bocciarelli, Head of Vector, shares one of the earliest warning signs that an AAV programme may struggle to scale as intended.
In this video, Daphné explains why variability can be an important early indicator of future scale-up challenges, whether that appears in titres, empty:full ratios, impurity profiles, or product stability. She also highlights the importance of understanding whether that variability comes from the process and can be improved, or whether it reflects product-specific behaviour that may present a more fundamental challenge during development.
What sets us apart:
Testimonials
Our Case Studies
Building a CMC Roadmap for an AAV-targeting Platform
Developed a strategic CMC roadmap for Tavira’s AAV-targeting platform, aligning internal teams and investors around clear priorities for clinical development.
Streamlining AAV Manufacturing for Clinical Scale-Up
Achieved GMP compliance through advanced optimisation, significantly enhancing yield and accelerating clinical readiness for a European biotech client’s AAV gene therapy.
Ready to discuss your AAV strategy?
Whether you’re planning your first GMP batch or refining a platform for later-stage studies, we can help you translate, optimise, and scale your AAV process with confidence. Contact us to start your AAV development journey with eXmoor Pharma.